Return to homepagePandemic Pact

ACE inhibition and cardiometabolic risk factors, lung ACE2 and TMPRSS2 expression, and plasma ACE2 levels: a Mendelian randomization study.

  • Funded by UK Research and Innovation (UKRI)
  • Total publications:0 publications

Grant number: C19-IUC-049

Grant search

Key facts

  • Disease

    COVID-19

  • Funder

    UK Research and Innovation (UKRI)

  • Principal Investigator

    Dipender Gill

  • Research Location

    United Kingdom

  • Lead Research Institution

    University of Bristol

  • Research Priority Alignment

    N/A

  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Disease pathogenesis

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Not applicable

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

Collaboration on project examining the impact of hypertensive drugs, statins and other co-morbidities (e.g. high BMI, Type 2 diabetes, hypertension) on the expression of receptors involved in COVID-19 infection (e.g. ACE2 and TMPRS22)